Ethiopia Group Antenatal Care Study at the Health Post Level (ARC004)

April 1, 2024 updated by: Jhpiego

Evaluation of the Feasibility, Acceptability and Impact of Group-based Antenatal Care at the Health Post Level on Continuation in Antenatal Care and Facility-based Delivery in Amhara, Ethiopia Using a Cluster Randomized Step-wedge Design

The purpose of this study is to determine the acceptability, feasibility, and effectiveness of a group antenatal care (G-ANC) model introduced at the health post level compared to usual antenatal care (ANC) among women who report intention to receive ANC at the health post level.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

540

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Mecha Woreda, West Gojam Zone, Amhara Region
      • Mecha, North Mecha Woreda, West Gojam Zone, Amhara Region, Ethiopia
        • Enashenifalen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 49 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Minimum age of 15 years at the time of enrollment; pregnant 15-17 year-olds will be treated as emancipated/mature as per local regulations
  • Gestational age less than or equal to 20 weeks at the time of enrollment determined by last menstrual period (LMP), pelvic exam, fundal height, quickening, ultrasound, and/or timing of fetal heart tones and pregnancy test
  • Pregnant women able and willing to provide adequate locator information
  • Planning to reside at their current location for at least 10 months
  • Agree to participate in the study and continue ANC at health post
  • Willing to participate and consent to follow up for up to 6 weeks post-delivery
  • Are willing to receive group antenatal care at the health post level (during the intervention period)

Exclusion Criteria:

  • Women who plan to travel away from the study site for more than four consecutive weeks during ANC or after 6 weeks post-delivery
  • Women who are unable provide consent
  • Women who have any condition that in the opinion of the investigator or designee, would complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group ANC
Intervention period in stepped wedge design where women are receiving antenatal care in a group setting
Group ANC is an integrated approach that incorporates physical assessment, education and skill development, and peer support and takes a broader, more holistic, woman-centered approach to traditional antenatal care
No Intervention: Individual ANC (routine)
Pre-intervention time period (control period) where the intervention is not being implemented yet (women are receiving individual antenatal care as is currently offered)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acceptability of G-ANC at the health post level
Time Frame: Less than or equal to 20 weeks gestation at enrollment into study up to 6 weeks after delivery
Satisfaction survey to understand satisfaction with G-ANC
Less than or equal to 20 weeks gestation at enrollment into study up to 6 weeks after delivery
Feasibility of G-ANC at the health post level
Time Frame: Less than or equal to 20 weeks gestation at enrollment into study up to 6 weeks after delivery
Documentation of number of G-ANC sessions facilitated by by health extension workers to measure feasibility
Less than or equal to 20 weeks gestation at enrollment into study up to 6 weeks after delivery
Effectiveness of G-ANC on continuation of ANC
Time Frame: Less than or equal to 20 weeks gestation at enrollment into study up to 6 weeks after delivery
Survey of self-reported number of ANC visits to document effectiveness of continuing ANC
Less than or equal to 20 weeks gestation at enrollment into study up to 6 weeks after delivery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effectiveness of G-ANC on quality of care
Time Frame: Less than or equal to 20 weeks gestation at enrollment into study up to 6 weeks after delivery
Survey of self-reported quality of care elements received during ANC to understand role of G-ANC on improving elements of quality of care during ANC
Less than or equal to 20 weeks gestation at enrollment into study up to 6 weeks after delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 20, 2021

Primary Completion (Actual)

February 28, 2024

Study Completion (Actual)

February 28, 2024

Study Registration Dates

First Submitted

August 11, 2021

First Submitted That Met QC Criteria

September 14, 2021

First Posted (Actual)

September 23, 2021

Study Record Updates

Last Update Posted (Actual)

April 2, 2024

Last Update Submitted That Met QC Criteria

April 1, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 14448

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified data will be shared with the Gates ARC partner, RTI

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Antenatal Care

Clinical Trials on Group Antenatal Care

Subscribe